Cholinesterase inhibitors for Alzheimer's disease
Hitzeman, N.
American Family Physician 74(5): 747-749
2006
ISSN/ISBN: 0002-838X PMID: 16970018 Document Number: 600923
Document emailed within 1 workday
Related Documents
Graipaspong, N.; Thaipisuttikul, P.; Vallipakorn, S.A.-O. 2016: Cholinesterase Inhibitors and Behavioral and Psychological Symptoms of Alzheimer's Disease Journal of the Medical Association of Thailand 99(4): 433-440Sinforiani, E.; Banchieri, L.M.; Zucchella, C.; Bernasconi, L.; Nappi, G. 2003: Cholinesterase inhibitors in Alzheimer's disease: efficacy in a non-selected population Functional Neurology 18(4): 233-237
Crismon, M.L. 1998: Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease PharmacoTherapy 18(2 Part 2): 47-54; Discussion: 79-82
Knott, V.; Mohr, E.; Mahoney, C.; Ilivitsky, V. 2000: Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease Methods and Findings in Experimental and Clinical Pharmacology 22(2): 115-122
Gillen, T.E.; Gregg, K.M.; Yuan, H.; Kurth, M.C.; Krishnan, K.R. 2001: Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease Psychopharmacology Bulletin 35(2): 83-96
Kłoszewska, I. 2002: Acetylcholinesterase inhibitors--beyond Alzheimer's disease Psychiatria Polska 36(6 Suppl): 133-141
Tomita, T. 2016: BACE1 inhibitors for the treatment of Alzheimer disease Nihon Rinsho. Japanese Journal of Clinical Medicine 74(3): 427-431
Sobów, T.M.; Kłoszewska, I. 1999: The costs of Alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use? Psychiatria Polska 33(5): 761-767
Giovannini, M.G.; Scali, C.; Prosperi, C.; Bellucci, A.; Pepeu, G.; Casamenti, F. 2003: Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors International Journal of Immunopathology and Pharmacology 16(2 Suppl): 31-40
Turon-Estrada, A.; López-Pousa, S.; Gelada-Batlle, E.; Garre-Olmo, J.; Lozano-Gallego, M.; Hernández-Ferràndiz, M.; Fajardo-Tibau, C.; Morante-Muñoz, V.; Vilalta-Franch, J. 2003: Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period Revista de Neurologia 36(5): 421-424
Mackell, J.A.; Ferris, S.H.; Mohs, R.; Schneider, L.; Galasko, D.; Whitehouse, P.; Schmitt, F.; Sano, M.; Thal, L.J. 1997: Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study Alzheimer Disease and Associated Disorders 11 Suppl. 2: S65-S69
Morris, J.C.; Edland, S.; Clark, C.; Galasko, D.; Koss, E.; Mohs, R.; van Belle, G.; Fillenbaum, G.; Heyman, A. 1993: The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease Neurology 43(12): 2457-2465
Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Takamaru, Y.; Sasaki, N.; Yoshida, T.; Hatakeyama, Y.; Fuji, N.; Takahata, N. 1997: Recent advances in Alzheimer's disease research--amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes Hokkaido Journal of Medical Science 72(1): 3-11
Morris, J.C.; Mohs, R.C.; Rogers, H.; Fillenbaum, G.; Heyman, A. 1988: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease Psychopharmacology Bulletin 24(4): 641-652
Miyakawa, T. 1988: Brain pathology in Alzheimer's disease. Ultrastructure of amyloid fibrils in Alzheimer's disease and Down's syndrome Nihon Rinsho. Japanese Journal of Clinical Medicine 46(7): 1471-1474
Szpak, G.M.; Lechowicz, W.; Lewandowska, E.; Bertrand, E.; Wierzba-Bobrowicz, T.; Gwiazda, E.; Schmidt-Sidor, B.; Dymecki, J. 2001: Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease. Quantitative study Folia Neuropathologica 39(3): 181-192
Ellis, J.M. 2005: Cholinesterase inhibitors in the treatment of dementia Journal of the American Osteopathic Association 105(3): 145-158
Petroianu, G.A.; Moshnin, W. 2008: The history of cholinesterase inhibitors: who was Moschnin(e)? Die Pharmazie 63(4): 325-327
Borchert, K.; Pietsch, P.; Busch, H. 1972: Use of cholinesterase inhibitors in postoperative care Zentralblatt für Chirurgie 97(4): 111-116
Bufill, E.; Blesa, R. 2006: Alzheimer's disease and brain evolution: is Alzheimer's disease an example of antagonistic pleiotropy? Revista de Neurologia 42(1): 25-33